Cardio.AI® logo — AI-powered platform for high-accuracy automatic annotation a...

Cardio.AI®

AI-powered platform for high-accuracy automatic annotation and interpretation of long ECG records.

Founded 2015 Latvia Latvia 11-50 employees Health Care, Information Technology +1

General Information

Company Name Cardio.AI®
Founded Year 2015
Location Latvia Latvia
Employees 11-50
Industries Health Care, Information Technology, Medical Devices
Social

Get notified when Cardio.AI® moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Cardio.AI®

XOresearch is a Latvia-based startup that has been operating since 2015. The company has developed a groundbreaking product named CardioAI, an AI-powered platform for high accuracy automatic annotation and interpretation of long and short ECG records. This proprietary software medical device utilizes deep learning technology to rapidly and accurately process ECG data, reducing the processing time for a single 24-hour ECG to about 30 seconds. This feature enables real-time monitoring and analysis of patients with heart conditions, offering physicians and caregivers an efficient tool to manage chronic conditions and potentially reduce non-essential hospitalizations. CardioAI is a feature-rich productivity tool designed to accelerate the interpretation of electrocardiograms, especially beneficial for prolonged or constant cardiac monitoring. It allows for better health surveillance in remote, difficult, or dangerous locations, providing accurate near real-time processing for unprecedented medical support. The software can be seamlessly integrated into an EHR system or incorporated into a mobile health device, making it adaptable to various business requirements. Notably, XOresearch takes data privacy seriously and their API does not accept any personal data with the signal, with reports modified on the client's side to add sensitive information. XOresearch operates at the intersection of healthcare and information technology industries, addressing a critical need for efficient cardiac monitoring and analysis. Although there is no available information about their latest investment or investors, the innovative nature of CardioAI and its potential to revolutionize cardiac care make XOresearch an intriguing prospect for venture capital firms seeking investment opportunities in the healthcare technology sector.

Taxonomy: AI-powered platform, deep learning technology, ECG interpretation, medical device software, real-time monitoring, cardiac conditions management, EHR integration, remote health surveillance, API implementation, data privacy, healthcare analytics, mobile health devices, artificial intelligence in healthcare, data processing

No funding data available for Cardio.AI® yet.

Get notified when Cardio.AI® raises funding

Cardio.AI® Alternatives & Competitors

Cardio.AI® vs
Walkky
Walkky United States

AI Platform for Cardiovascular Diagnosis

Non Equity Assistance
7 employees
Analytics, Health Care

FAQ About Cardio.AI®

AI-powered platform for high-accuracy automatic annotation and interpretation of long ECG records.
Cardio.AI® was founded in 2015.
Cardio.AI® is headquartered in Latvia.
Cardio.AI® operates in the following industries: Health Care, Information Technology, Medical Devices.
Cardio.AI® has approximately 11-50 employees.
Top alternatives and competitors to Cardio.AI® include Walkky. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cardio.AI® and Walkky are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Cardio.AI® and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes